METTL5

Across TCGA pan-cancer cohorts, METTL5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated METTL5 data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher METTL5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated METTL5 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where METTL5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.786	1.000	.001	49	view →
HNSC	OS	Median	All	0.909	0.800	.004	22	view →
PDAC	OS	Median	All	0.293	0.554	.008	18	view →
GBM	OS	Quartile	All	0.687	0.409	.006	10	view →
LSCC	OS	Quartile	II,III,IV	0.603	1.000	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

METTL5–CCRCC (DFS)

Open the CCRCC breakdown →